In the context of a brain tumor, it is therefore possible that the TGF-β-induced SHP proteins interact with IFN-γ-induced IDO, resulting in the release of RelB, interaction with Ahr and downstream effects that include the activation of CCL22 transcription (Figure 3). The gene discussed is IDO1; the disease is brain neoplasm.